Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Casodex(R) Tablets
Date:7/7/2009

DETROIT, July 7 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) has launched Bicalutamide tablets on behalf of Sun Pharmaceutical Industries Ltd. (Sun Pharma), immediately following Sun Pharma's recently received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for generic Casodex(R) tablets.

Bicalutamide tablets are an androgen receptor inhibitor indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of the prostate. This generic version of Bicalutamide 50 mg tablets is bioequivalent to Casodex(R) which is a registered trademark of AstraZeneca group of companies. According to IMS Data, Casodex had US sales of approximately $314 million for the calendar year of 2008.

Daniel H. Movens, Caraco's Chief Executive Officer, said, "We are pleased to add this product to our portfolio by launching Bicalutamide tablets immediately to the marketplace. We continue to focus on working towards expanding our product offering as quickly and effectively as possible."

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission and include, but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or cheaper products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Methimazole Tablets USP, 5 mg and 10 mg
2. Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation from Board of Directors of Jitendra Doshi and Appointment of GP Singh Sachdeva
3. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009
4. Caraco Pharmaceutical Laboratories Ltd. to Announce Second Quarter of Fiscal Year 2009 Results on October 23, 2008
5. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009
6. Caraco Pharmaceutical Laboratories, Ltd. Receives FDA Warning Letter
7. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
8. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 3, 2016 ... Assessing Developers and Producers of Those Competitor Biologics  ... to Companies, Activities and Prospects ,  Who ... companies? And what are their sales potentials? Discover, ... you see results, trends, opportunities and revenue forecasting. ...
(Date:5/2/2016)... , May 2, 2016 Q ... its technology partner Mannin Research Inc. will be attending ... which takes place from May 1-5, 2016 in ... be meeting with its vendors and research partners. The ... development goals and other collaborative opportunities for the MAN-01 ...
(Date:4/29/2016)... ... 30, 2016 , ... The MIT bioLogic design team has won multiple ... bacterial properties can be applied to fabric and formed into living interfaces between body ... to humidity change. The team harvested Natto cells and applied them to fabric with ...
(Date:4/29/2016)... ... April 29, 2016 , ... During a two ... into a viable company, CereScan’s CEO, John Kelley, joined other Denver business leaders ... and mentor in the Denver area business community, shared his top fundamental learnings ...
Breaking Biology Technology:
(Date:3/22/2016)... , PROVO and ... -- Newborn Screening Ontario (NSO), which operates the highest ... for molecular testing, and Tute Genomics and UNIConnect, leaders ... technology respectively, today announced the launch of a project ... sequencing (NGS) testing panel. NSO has ...
(Date:3/15/2016)... , March 15, 2016 Yissum ... , the technology-transfer company of the Hebrew University, announced ... of remote sensing technology of various human biological indicators. ... raising $2.0 million from private investors. ... based on the detection of electromagnetic emissions from sweat ...
(Date:3/10/2016)... 2016 --> ... "Identity and Access Management Market by Component (Provisioning, Directory ... by Organization Size, by Deployment, by Vertical, and by ... The market is estimated to grow from USD 7.20 ... at a Compound Annual Growth Rate (CAGR) of 12.2% ...
Breaking Biology News(10 mins):